Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Beats on EPS, Stock Up 0.59%

Arrowhead Pharmaceuticals reported a narrower loss than expected, which led to a slight increase in stock price by 0.59%. However, there was no revenue reported or guidance provided, leaving investors with limited insight into future performance. The positive EPS surprise may indicate some operational efficiency, but the lack of revenue information raises questions about overall business health.